Therapeutic Drugs and Devices for Tackling Ocular Hypertension and Glaucoma, and Need for Neuroprotection and Cytoprotective Therapies

Sharif N.

2021
Frontiers in Pharmacology

Therapeutic Area

Glaucoma
Categories

Disease understanding (epidemiology, diagnosis, QoL, Biomarkers…)

Affiliations

Global Alliances and External Research, Ophthalmology Innovation Center, Santen Inc, Emeryville, CA, United States

Related Publications

Felodipine re-positioned as a neuroprotectant via improved optic nerve head blood circulation in retinal ischemic rabbits and ocular hypertensive rats

Taniguchi T, Akaishi T, Hata T, Yamashita R, Esaki Y, Morofuji R, Okabe K, Fuwa M, Yamamoto Y, Guo L, Choi S, Luong V, Ota T, Sharif NA, Cordeiro MF, Kageyama M.

A Study of 24-h Efficacy and Safety of Sepetaprost vs. Latanoprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension

Konstas A.G.; Garhöfer G.; Lübke Y.; Voykov B.; Ropo A.

Valproic Acid Application to Modify Post Surgical Fibrosis in a Model of Minimally Invasive Bleb Surgery

Lo P.F.; Gunawan M.; Yap Z.L.; Leong C.; Kwek F.; Varadarajan J.; Wang X.; Kageyama M.; Wong T.T.

View all Glaucoma publications